|
EP0932405A4
(en)
|
1996-06-27 |
2001-10-17 |
Smithkline Beckman Corp |
IL-8 RECEPTOR ANTAGONISTS
|
|
AU8673198A
(en)
*
|
1997-07-29 |
1999-02-22 |
Smithkline Beecham Corporation |
Il-8 receptor antagonists
|
|
US20080300281A1
(en)
*
|
1997-12-22 |
2008-12-04 |
Jacques Dumas |
Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
CA2318195A1
(en)
*
|
1998-01-16 |
1999-07-22 |
Deborah Lynne Bryan |
Il-8 receptor antagonists
|
|
UY25842A1
(es)
*
|
1998-12-16 |
2001-04-30 |
Smithkline Beecham Corp |
Antagonistas de receptores de il-8
|
|
US20080269265A1
(en)
*
|
1998-12-22 |
2008-10-30 |
Scott Miller |
Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
US6767922B2
(en)
|
2000-03-14 |
2004-07-27 |
Smithkline Beecham Corporation |
IL-8 receptor antagonists
|
|
AR030689A1
(es)
*
|
2000-03-14 |
2003-09-03 |
Smithkline Beecham Corp |
Compuestos de 3-aminosulfonil-2-hidroxifenil urea, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades mediadas por quimioquinas
|
|
JP2003527360A
(ja)
*
|
2000-03-14 |
2003-09-16 |
スミスクライン・ビーチャム・コーポレイション |
Ｉｌ−８受容体アンタゴニスト
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
CN1289471C
(zh)
*
|
2001-04-16 |
2006-12-13 |
先灵公司 |
作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮
|
|
US7371763B2
(en)
*
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
WO2003047579A1
(en)
*
|
2001-12-03 |
2003-06-12 |
Bayer Pharmaceuticals Corporation |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
ATE529406T1
(de)
*
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
US20040023961A1
(en)
*
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
TW200418812A
(en)
*
|
2002-10-29 |
2004-10-01 |
Smithkline Beecham Corp |
IL-8 receptor antagonists
|
|
WO2004058722A1
(en)
*
|
2002-12-24 |
2004-07-15 |
Arena Pharmaceuticals, Inc. |
Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
DE602004000260T2
(de)
*
|
2003-07-22 |
2006-08-24 |
Arena Pharmaceuticals, Inc., San Diego |
Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
ATE548353T1
(de)
*
|
2004-03-23 |
2012-03-15 |
Arena Pharm Inc |
Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
|
|
EP2295426A1
(en)
*
|
2004-04-30 |
2011-03-16 |
Bayer HealthCare, LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
CN1984899B
(zh)
|
2004-05-12 |
2011-07-27 |
先灵公司 |
Cxcr1和cxcr2趋化因子拮抗剂
|
|
EP1812008A4
(en)
*
|
2004-10-20 |
2008-10-29 |
Smithkline Beecham Corp |
ANTAGONISTS OF THE IL-8 RECEPTOR
|
|
SA05260357B1
(ar)
|
2004-11-19 |
2008-09-08 |
ارينا فارماسيتو تيكالز ، أنك |
مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
|
|
US20080015223A1
(en)
*
|
2004-12-03 |
2008-01-17 |
Arena Pharmaceuticals, Inc. |
Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
|
|
US20080200530A1
(en)
*
|
2005-01-19 |
2008-08-21 |
Unett David J |
Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy
|
|
EP1851188A1
(en)
*
|
2005-02-22 |
2007-11-07 |
Teva Pharmaceutical Industries Limited |
Improved process for the synthesis of enantiomeric indanylamine derivatives
|
|
PL2009992T3
(pl)
*
|
2006-04-21 |
2012-11-30 |
Glaxosmithkline Llc |
Antagoniści receptora IL-8
|
|
US8097626B2
(en)
|
2006-04-21 |
2012-01-17 |
Glaxosmithkline Llc |
IL-8 receptor antagonists
|
|
JP5406018B2
(ja)
|
2006-05-18 |
2014-02-05 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５−ｈｔ２ａセロトニンレセプターに関連する障害の処置に有用な５−ｈｔ２ａセロトニンレセプターのモジュレーターとしての１級アミン、およびその誘導体
|
|
CA2646076C
(en)
*
|
2006-05-18 |
2015-06-30 |
Arena Pharmaceuticals, Inc. |
Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
SG171681A1
(en)
|
2006-05-18 |
2011-06-29 |
Arena Pharm Inc |
Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
|
|
CL2007001829A1
(es)
*
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
|
|
JP5393677B2
(ja)
|
2007-08-15 |
2014-01-22 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
|
|
US20110021538A1
(en)
*
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
CA2741731A1
(en)
*
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
|
|
WO2011075596A1
(en)
|
2009-12-18 |
2011-06-23 |
Arena Pharmaceuticals, Inc. |
Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
US10022355B2
(en)
|
2015-06-12 |
2018-07-17 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
|
|
BR112018000728A2
(pt)
|
2015-07-15 |
2018-09-04 |
Axovant Sciences Gmbh |
resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
|